EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Direct oral anticoagulants compared to warfarin in long‐term management of cerebral venous thrombosis: A comprehensive meta‐analysis

Redoy Ranjan iD, Gie Ken-Dror, Pankaj Sharma

Health Science Reports · 2024-02 · 7 (2)

DOI: 10.1002/hsr2.1869 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Health Science Reports, online erschienen am 04.02.2024. Verfasst von Redoy Ranjan und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiac Surgery Bangabandhu Sheikh Mujib Medical University Dhaka Bangladesh. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

We compared the safety and efficacy of direct oral anticoagulants (DOACs) with those of warfarin in the long‐term (≥6 months) treatment of cerebral venous thrombosis (CVT).

Methods

We searched electronic databases up to November 2023 to compare the use of DOACs and warfarin in CVT management. Modified Rankin scores (mRS), new intracranial hemorrhage, all‐cause mortality, recurrence and nonrecanalisation events were used to assess outcome. RevMan v5.4 software and the Cochran‐Mantel‐Haenszel method were utilized to analyse data.

Results

A total of 25 studies involving 2301 patients were identified as having treated CVT with either DOACs or warfarin. Good long‐term mRS scores 0–2 (risk ratio [RR] = 1.01, 95% CI = 0.98–1.03; p = 0.61), new intracranial hemorrhage (RR = 1.00, 95% CI = 0.48–2.08; p = 0.99), all‐cause mortality (RR = 1.00, 95% CI = 0.50–1.98; p = 0.99), nonrecanalisation (RR = 0.95, 95% CI = 0.77–1.18; p = 0.65) and recurrence venous thrombosis events (RR = 0.63, 95% CI = 0.33–1.22; p = 0.17) were similar between the two treatment arms. Subgroup analysis found recurrence of venous thrombosis was lower in the rivaroxaban group compared to warfarin (2.2% vs. 8.5%, RR = 0.33, 95% CI = 0.11–0.98; p = 0.05).

Conclusion

DOACs and warfarin provide comparable long‐term safety and efficacy profiles. DOACs may be preferred over warfarin due to their ease of clinical management.

Schlagwörter

Stichwörter der Autor:innen

apixabancerebral venous thrombosisdabigatrandirect oral anticoagulantsedoxabanefficacyrivaroxabansafetywarfarin

Autor:innen und Institutionen

  • Department of Cardiac Surgery Bangabandhu Sheikh Mujib Medical University Dhaka Bangladesh.
  • Institute of Cardiovascular Research Royal Holloway University of London (ICR2UL) Greater London UK.
  • Department of Clinical Neurology Imperial College London Healthcare NHS Trust London UK.

ORCID-Profile: Redoy Ranjan

Zitieren

APA

Ranjan, R., Ken-Dror, G., & Sharma, P. (2024). Direct oral anticoagulants compared to warfarin in long‐term management of cerebral venous thrombosis: A comprehensive meta‐analysis. Health Science Reports, 7(2). https://doi.org/10.1002/hsr2.1869

Vancouver

Ranjan R, Ken-Dror G, Sharma P. Direct oral anticoagulants compared to warfarin in long‐term management of cerebral venous thrombosis: A comprehensive meta‐analysis. Health Science Reports. 2024;7(2). doi:10.1002/hsr2.1869

BibTeX
@article{Ranjan2024,
  author = {Ranjan, Redoy and Ken-Dror, Gie and Sharma, Pankaj},
  title = {Direct oral anticoagulants compared to warfarin in long‐term management of cerebral venous thrombosis: A comprehensive meta‐analysis},
  journal = {Health Science Reports},
  year = {2024},
  volume = {7},
  number = {2},
  doi = {10.1002/hsr2.1869}
}
Kostenlos starten →